A Phase I Trial of an IV-Administered Vascular Endothelial Growth Factor Trap for Treatment in Patients with Choroidal Neovascularization due to Age-Related Macular Degeneration

Quan Dong Nguyen, Syed Mahmood Shah, Gulnar Hafiz, Edward Quinlan, Jennifer Sung, Karen Chu, Jesse M. Cedarbaum, Peter A Campochiaro

Research output: Contribution to journalArticle

Abstract

Objectives: To assess the safety, pharmacokinetics, and biological activity of IV administration of vascular endothelial growth factor trap (VEGF Trap), a recombinant protein containing the binding domains of VEGF receptors 1 and 2, in patients with neovascular age-related macular degeneration (AMD). Design: Randomized, multicenter, placebo-controlled clinical trial. Participants: Twenty-five patients were enrolled (11 male, 14 female); 19 received VEGF Trap (0.3 [n = 7], 1.0 [n = 7], or 3.0 mg/kg [n = 5]), and 6 received a placebo. Methods: Patients were randomized to receive a placebo or 0.3-, 1.0-, or 3.0-mg/kg VEGF Trap-a single IV dose followed by a 4-week observation period and then 3 doses 2 weeks apart. Main Outcome Measures: Safety and biological activity, including change in excess retinal thickness and volume assessed by optical coherence tomography and visual acuity (VA) measured by the Early Treatment Diabetic Retinopathy Study protocol. Results: The majority of adverse events attributable to VEGF Trap were mild to moderate in severity, but 2 of 5 patients treated with 3.0 mg/kg experienced dose-limiting toxicity (1 with grade 4 hypertension and 1 with grade 2 proteinuria); therefore, all patients in the 3.0 mg/kg-dose group were withdrawn from the study. The mean percent changes in excess retinal thickness were -12%, -10%, -66%, and -60%, respectively, for the placebo and 0.3-, 1.0-, and 3.0-mg/kg groups at day 15 (P

Original languageEnglish (US)
JournalOphthalmology
Volume113
Issue number9
DOIs
StatePublished - Sep 2006

Fingerprint

Choroidal Neovascularization
Macular Degeneration
Vascular Endothelial Growth Factor A
Placebos
Therapeutics
Safety
Vascular Endothelial Growth Factor Receptor
Controlled Clinical Trials
Optical Coherence Tomography
Diabetic Retinopathy
Proteinuria
Recombinant Proteins
Protein Binding
Visual Acuity
Pharmacokinetics
Observation
Outcome Assessment (Health Care)
Hypertension

ASJC Scopus subject areas

  • Ophthalmology

Cite this

A Phase I Trial of an IV-Administered Vascular Endothelial Growth Factor Trap for Treatment in Patients with Choroidal Neovascularization due to Age-Related Macular Degeneration. / Nguyen, Quan Dong; Shah, Syed Mahmood; Hafiz, Gulnar; Quinlan, Edward; Sung, Jennifer; Chu, Karen; Cedarbaum, Jesse M.; Campochiaro, Peter A.

In: Ophthalmology, Vol. 113, No. 9, 09.2006.

Research output: Contribution to journalArticle

@article{789c82af6af844bfa2bbf0721f7b23bf,
title = "A Phase I Trial of an IV-Administered Vascular Endothelial Growth Factor Trap for Treatment in Patients with Choroidal Neovascularization due to Age-Related Macular Degeneration",
abstract = "Objectives: To assess the safety, pharmacokinetics, and biological activity of IV administration of vascular endothelial growth factor trap (VEGF Trap), a recombinant protein containing the binding domains of VEGF receptors 1 and 2, in patients with neovascular age-related macular degeneration (AMD). Design: Randomized, multicenter, placebo-controlled clinical trial. Participants: Twenty-five patients were enrolled (11 male, 14 female); 19 received VEGF Trap (0.3 [n = 7], 1.0 [n = 7], or 3.0 mg/kg [n = 5]), and 6 received a placebo. Methods: Patients were randomized to receive a placebo or 0.3-, 1.0-, or 3.0-mg/kg VEGF Trap-a single IV dose followed by a 4-week observation period and then 3 doses 2 weeks apart. Main Outcome Measures: Safety and biological activity, including change in excess retinal thickness and volume assessed by optical coherence tomography and visual acuity (VA) measured by the Early Treatment Diabetic Retinopathy Study protocol. Results: The majority of adverse events attributable to VEGF Trap were mild to moderate in severity, but 2 of 5 patients treated with 3.0 mg/kg experienced dose-limiting toxicity (1 with grade 4 hypertension and 1 with grade 2 proteinuria); therefore, all patients in the 3.0 mg/kg-dose group were withdrawn from the study. The mean percent changes in excess retinal thickness were -12{\%}, -10{\%}, -66{\%}, and -60{\%}, respectively, for the placebo and 0.3-, 1.0-, and 3.0-mg/kg groups at day 15 (P",
author = "Nguyen, {Quan Dong} and Shah, {Syed Mahmood} and Gulnar Hafiz and Edward Quinlan and Jennifer Sung and Karen Chu and Cedarbaum, {Jesse M.} and Campochiaro, {Peter A}",
year = "2006",
month = "9",
doi = "10.1016/j.ophtha.2006.05.055",
language = "English (US)",
volume = "113",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - A Phase I Trial of an IV-Administered Vascular Endothelial Growth Factor Trap for Treatment in Patients with Choroidal Neovascularization due to Age-Related Macular Degeneration

AU - Nguyen, Quan Dong

AU - Shah, Syed Mahmood

AU - Hafiz, Gulnar

AU - Quinlan, Edward

AU - Sung, Jennifer

AU - Chu, Karen

AU - Cedarbaum, Jesse M.

AU - Campochiaro, Peter A

PY - 2006/9

Y1 - 2006/9

N2 - Objectives: To assess the safety, pharmacokinetics, and biological activity of IV administration of vascular endothelial growth factor trap (VEGF Trap), a recombinant protein containing the binding domains of VEGF receptors 1 and 2, in patients with neovascular age-related macular degeneration (AMD). Design: Randomized, multicenter, placebo-controlled clinical trial. Participants: Twenty-five patients were enrolled (11 male, 14 female); 19 received VEGF Trap (0.3 [n = 7], 1.0 [n = 7], or 3.0 mg/kg [n = 5]), and 6 received a placebo. Methods: Patients were randomized to receive a placebo or 0.3-, 1.0-, or 3.0-mg/kg VEGF Trap-a single IV dose followed by a 4-week observation period and then 3 doses 2 weeks apart. Main Outcome Measures: Safety and biological activity, including change in excess retinal thickness and volume assessed by optical coherence tomography and visual acuity (VA) measured by the Early Treatment Diabetic Retinopathy Study protocol. Results: The majority of adverse events attributable to VEGF Trap were mild to moderate in severity, but 2 of 5 patients treated with 3.0 mg/kg experienced dose-limiting toxicity (1 with grade 4 hypertension and 1 with grade 2 proteinuria); therefore, all patients in the 3.0 mg/kg-dose group were withdrawn from the study. The mean percent changes in excess retinal thickness were -12%, -10%, -66%, and -60%, respectively, for the placebo and 0.3-, 1.0-, and 3.0-mg/kg groups at day 15 (P

AB - Objectives: To assess the safety, pharmacokinetics, and biological activity of IV administration of vascular endothelial growth factor trap (VEGF Trap), a recombinant protein containing the binding domains of VEGF receptors 1 and 2, in patients with neovascular age-related macular degeneration (AMD). Design: Randomized, multicenter, placebo-controlled clinical trial. Participants: Twenty-five patients were enrolled (11 male, 14 female); 19 received VEGF Trap (0.3 [n = 7], 1.0 [n = 7], or 3.0 mg/kg [n = 5]), and 6 received a placebo. Methods: Patients were randomized to receive a placebo or 0.3-, 1.0-, or 3.0-mg/kg VEGF Trap-a single IV dose followed by a 4-week observation period and then 3 doses 2 weeks apart. Main Outcome Measures: Safety and biological activity, including change in excess retinal thickness and volume assessed by optical coherence tomography and visual acuity (VA) measured by the Early Treatment Diabetic Retinopathy Study protocol. Results: The majority of adverse events attributable to VEGF Trap were mild to moderate in severity, but 2 of 5 patients treated with 3.0 mg/kg experienced dose-limiting toxicity (1 with grade 4 hypertension and 1 with grade 2 proteinuria); therefore, all patients in the 3.0 mg/kg-dose group were withdrawn from the study. The mean percent changes in excess retinal thickness were -12%, -10%, -66%, and -60%, respectively, for the placebo and 0.3-, 1.0-, and 3.0-mg/kg groups at day 15 (P

UR - http://www.scopus.com/inward/record.url?scp=33747874091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747874091&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2006.05.055

DO - 10.1016/j.ophtha.2006.05.055

M3 - Article

C2 - 16876249

AN - SCOPUS:33747874091

VL - 113

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 9

ER -